ProPhase Labs, Inc. (PRPH) stock

PRPHOTCPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 0/30

$0.01−0.00 (-6.16%)

Close on Oct 19, 2026Market cap $119.68KP/E –Yield –

ProPhase Labs EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

ProPhase Labs's EV/EBITDA was 8.7× on Jul 31, 2023, against 4.5× a year earlier. Over the last 2 years it ranged from 2.1× to 134.2×, with a median of 6.7×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2023	Jul 31, 2023	8.7×	+6.0
2022	Dec 30, 2022	2.6×	−3.2
2021	Jul 30, 2021	5.8×	−39.7
2014	Jan 31, 2014	45.4×	+10.4
2013	Dec 31, 2013	35.0×	–

Where these numbers come from

Parsed from the XBRL in ProPhase Labs's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10.33 reverse split on Jun 1, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRPH.

Compare: PRPH vs PTCHF · PRPH vs IMNM · PRPH vs ANL · PRPH vs PTPI · PRPH vs APLM

Company	Revenue	Growth
IMNM	$4.02M	-63.3%
PRPH	$3.85M	-31.2%
PTCHF	–	–
ANL	–	–
PTPI	–	–
APLM	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 19
Held by institutions: 0.0%
Auditor: Fruci & Associates II, PLLC
SEC CIK: 868278

Advertisement
300 × 250

See a number that looks wrong?

ProPhase Labs EV/EBITDA

EV/EBITDA at the end of each year

More ProPhase Labs figures